Research and Markets: Gain an Understanding of the Complex Issues Affecting Sandoz the Generics Company

Business Wire, April 26, 2006

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36147) has announced the addition of the Espicom Business Intelligence Ltd report: Sandoz Generics Company Intelligence Report to their offering.

Our generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

Topics Covered

INTRODUCTION

Canada

PRODUCTS

Sandoz ANDA Approvals, 2002-06

Geneva Pharmaceuticals ANDA Approvals, 2002-03

Lek ANDA Approvals, 2002-03

Eon Labs ANDA Approvals, 2002-05

Recent product approvals

Sandoz

EU positive opinion for Omnitrope

US zonisamide approval

US cefprozil approval

US azithromycin approval

US leflunomide approval

US ceftriaxone injection launch announced

Australian TGA approves Omnitrope

Recent product approvals

Hexal

Tramadol (Labopharm)

Fentanyl patch

Recent product approvals

Eon Labs

Bupropion hydrochloride

Recent product approvals

Lek

Leks pravastatin launched in Europe

FINANCIAL RESULTS

Latest Yearly Results

Sandoz: 2005 results (US$ millions)

Latest Quarterly Results

Sandoz: fourth quarter 2005 results (US$ millions)

MAJOR DEVELOPMENTS

Facilities

Lek opens new facility in Slovenia

Mergers, acquisitions and agreements

Momenta and Sandoz develop generic M-enoxaparin

Sandoz completes purchase of Hexal and Eon Labs

Novartis India plans to transfer facility to Sandoz

Sabex

SANDOZ GENERIC COMPANIES ANALYSIS

ii Quarter I, 2006

Durascan

Amifarma

Lek acquisition

Litigation

Pfizer petitions the FDA to recall Tevas and Sandoz azithromycin products

AstraZeneca and Eon Labs in metoprolol patent litigation

Sandoz files lawsuit against FDA regarding Omnitrope

Amoxicillin and clavulanate

Summary

Sandoz, headquartered in Holzkirchen, Germany, is the generics business of Novartis, and makes up part of Novartis' Consumer Health Division. Sandoz had previously been based in Vienna, Austria, but moved to the German site in 2005 as a consequence of the Hexal acquisition; the site had been the home of the Hexal HQ.

Prior to Sandoz' re-branding in May 2003, Novartis' generics business had been made up of 14 separate firms. The re-branding was completed in 2005, with the exception of Lek, which remains a separate Slovenia-based company for the time being. The company is one of the largest generic pharmaceuticals businesses in the world. Sandoz currently employs over 20,000 people in 110 countries. It operates through three business franchises:

--The Pharmaceuticals Business produces finished dosage forms, which are sold to pharmacies, hospitals and other healthcare outlets;

--The Biopharmaceutical Business draws on the company's experience with biotechnology, and is expanding to meet demand;

--The Industrial Business manufactures active pharmaceutical ingredients and their intermediates for internal requirements and industrial partners.

For more information visit http://www.researchandmarkets.com/reports/c36147